CERS Strangle Strategy
CERS (Cerus Corporation), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
CERS (Cerus Corporation) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $521.0M, a beta of 1.63 versus the broader market, a 52-week range of 1.15-3.15, average daily share volume of 2.1M, a public-listing history dating back to 1997, approximately 614 full-time employees. These structural characteristics shape how CERS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.63 indicates CERS has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on CERS?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CERS snapshot
As of May 15, 2026, spot at $2.37, ATM IV 108.70%, IV rank 18.47%, expected move 31.16%. The strangle on CERS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this strangle structure on CERS specifically: CERS IV at 108.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a CERS strangle, with a market-implied 1-standard-deviation move of approximately 31.16% (roughly $0.74 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CERS expiries trade a higher absolute premium for lower per-day decay. Position sizing on CERS should anchor to the underlying notional of $2.37 per share and to the trader's directional view on CERS stock.
CERS strangle setup
The CERS strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CERS near $2.37, the first option leg uses a $2.49 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CERS chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CERS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $2.49 | N/A |
| Buy 1 | Put | $2.25 | N/A |
CERS strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CERS strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CERS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CERS
Strangles on CERS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CERS chain.
CERS thesis for this strangle
The market-implied 1-standard-deviation range for CERS extends from approximately $1.63 on the downside to $3.11 on the upside. A CERS long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CERS IV rank near 18.47% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CERS at 108.70%. As a Healthcare name, CERS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CERS-specific events.
CERS strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CERS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CERS alongside the broader basket even when CERS-specific fundamentals are unchanged. Always rebuild the position from current CERS chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CERS?
- A strangle on CERS is the strangle strategy applied to CERS (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CERS stock trading near $2.37, the strikes shown on this page are snapped to the nearest listed CERS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CERS strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CERS strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 108.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CERS strangle?
- The breakeven for the CERS strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CERS market-implied 1-standard-deviation expected move is approximately 31.16%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CERS?
- Strangles on CERS are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CERS chain.
- How does current CERS implied volatility affect this strangle?
- CERS ATM IV is at 108.70% with IV rank near 18.47%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.